logo

For the Inventor, By the Inventor

Munich, Germany

Wilex Ag


USPTO Granted Patents = 36

% Expired Patents = 44.4



Forward Citations = 197

Loading Chart...
Loading Chart...

51 inventors (with patents filed for the assignee):

goldMedal Olaf G Wilhelm (11 out of 15 patents)

silverMedal Viktor Magdolen (8 out of 12 patents)

bronzeMedal Stefan Sperl (8 out of 10 patents)

4.  Manfred Schmitt (5 out of 15 patents)

5.  Hugo Ziegler (5 out of 39 patents)

6.  Peter Wikstroem (5 out of 13 patents)

7.  Horst Kessler (4 out of 35 patents)

8.  Sven Warnaar (4 out of 4 patents)

9.  Wolfgang Schmalix (4 out of 4 patents)

10.  Jörg Stürzebecher (4 out of 7 patents)

11.  Markus Buergle (4 out of 4 patents)

12.  Stefan Ullrich (3 out of 7 patents)

13.  Markus Bürgle (3 out of 3 patents)

14.  Luis Moroder (3 out of 12 patents)

15.  Thomas Luther (3 out of 3 patents)


Core Competencies:
Cancer Treatment
Monoclonal Antibodies
Urokinase Inhibitors
Phenylalanine Derivatives
G250 Antibody
Hydroxyamidine Compounds
Cyclic Peptidomimetics
Diagnostic Methods
Tumor Prognosis
Neuropathological Diseases
Selective Inhibitors
Epitopes

36 patents:

1. 10620208 - Classifying a cancer disease using CAIX expression (2020-04-14),
2. RE46424 - Method for producing 3-amidinophenylalanine derivatives (2017-06-05),
3. 9605075 - Hybridoma cell line G250 and its use for producing monoclonal antibodies (2017-03-28),
4. 9089532 - Stable dosage form of phenylalanine derivatives (2015-07-28),
5. 8828381 - Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas (2014-09-09),
6. 8642761 - Method for producing 3-amidinophenylalanine derivatives (2014-02-04),
7. 8492520 - Binding epitopes for G250 antibody (2013-07-23),
8. 8492385 - Crystalline modifications of N-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof (2013-07-23),
9. 8461321 - Nucleic acids encoding a deletion variant of uPAR (2013-06-11),
10. 8093258 - Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases (2012-01-10),
11. 8088921 - Method for producing 3-amidinophenylalanine derivatives (2012-01-03),
12. 7951943 - Method for preparing and purifying 3-hydroxyamidinophenylalanine compounds (2011-05-31),
13. 7951589 - Monoclonal antibodies specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor (2011-05-31),
14. 7884206 - Method for producing 3-amidinophenylalanine derivatives (2011-02-08),
15. 7807681 - Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors (2010-10-05),
Company Overview
Wilex AG is a biotechnology company based in Munich, Germany, specializing in the development of innovative therapeutic solutions for cancer treatment. The organization focuses on the research and commercialization of targeted therapies and diagnostic tools, aiming to improve patient outcomes in oncology. Wilex leverages advanced technologies to create novel approaches in the fight against cancer, emphasizing the importance of precision medicine and personalized treatment strategies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

36 Patents

#91 in W-8000 Munich

#1,396 in Germany

#18,730 in the World

Munich, DE
Munich, Germany

Wilex Ag

Forward Citations = 197

51 inventors:

goldMedal Olaf G Wilhelm (11 out of 15 patents)

silverMedal Viktor Magdolen (8 out of 12 patents)

bronzeMedal Stefan Sperl (8 out of 10 patents)

4.  Manfred Schmitt (5 out of 15 patents)

5.  Hugo Ziegler (5 out of 39 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Wilex Ag. Retrieved from https://idiyas.com/company/wilex-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…